Sunday 11 October 2026
Export all MRK data to Excel Powerpack
Merck & Co., Inc.
MRK Healthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS fell 130.7%, free cash flow grew 77.0% and total debt rose 50.4%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for five.
145.60
3.22
+2.26%
Follow MRK
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
39.46% | 36.86% | 18.94% | 6.97% | |
Piotroski F-Score |
6 | 4 | 4 | 4 | |
| 15.41% | 14.37% | 7.33% | 2.57% | ||
ROIC |
19.00% | 16.28% | 9.33% | 5.08% | |
Return on Tangible Assets |
42.71% | 45.07% | 26.67% | 9.15% | |
Average Days of Receivables |
68.87 | 66.11 | 67.76 | 68.89 | |
Free Cash Flow per Share |
5.23 | 4.94 | 5.71 | 6.50 | |
Free Cash Flow |
13,049.00 | 12,360.00 | 14,115.00 | 16,063.00 | |
Capital Expenditures |
(4,016.00) | (4,112.00) | (3,775.00) | (3,904.00) | |
| Other line items | |||||
Cash ROIC |
11.85% | 10.84% | 14.36% | 16.03% | |
Accounts Receivable Turnover |
5.47 | 5.90 | 5.72 | 5.45 | |
Accounts Payable Turnover |
3.79 | 3.86 | 4.49 | 4.66 | |
Inventory Turnover |
2.31 | 2.57 | 2.71 | 2.81 | |
Average Days of Payables |
103.26 | 98.12 | 82.18 | 77.62 | |
Days of Inventory on Hand |
160.45 | 148.34 | 137.83 | 125.89 | |
Tax Rate |
(0.13) | (0.13) | (0.23) | (0.47) | |
Research and Development Expense of Revenue |
25.67% | 24.29% | 37.65% | 45.75% | |
Selling, General and Administrative Expense of Revenue |
16.65% | 16.51% | 16.54% | 16.73% | |
Share Based Compensation of Revenue |
1.25% | 1.26% | 1.23% | 1.34% | |
Operating CF/Net income |
0.90 | 0.90 | 2.00 | 6.29 | |
Depreciation/Fixed assets |
0.18 | 0.23 | 0.25 | 0.26 | |
Capex/Depreciation |
(0.88) | (0.70) | (0.60) | (0.58) | |
Revenue per Share |
25.75 | 25.98 | 26.61 | 26.95 | |
Operating CF per Share |
6.84 | 6.58 | 7.24 | 8.08 | |
Capex per Share |
(1.61) | (1.64) | (1.53) | (1.58) | |
Capex to Sales |
0.06 | 0.06 | 0.06 | 0.06 |
Columns are period end dates